SU11274
Names
[ CAS No. ]:
658084-23-2
[ Name ]:
SU11274
[Synonym ]:
(3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxoindoline-5-sulfonamide
(3Z)-N-(3-Chlorophenyl)-3-({3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl}methylene)-N-methyl-2-oxo-5-indolinesulfonamide
1H-Indole-5-sulfonamide, N-(3-chlorophenyl)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-N-methyl-2-oxo-, (3Z)-
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)
(3Z)-N-(3-Chlorophenyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide
Met Kinase Inhibitor
SU11274
Biological Activity
[Description]:
[Related Catalog]:
[Target]
IC50: 10 nM (Met)[1]
[In Vitro]
[Kinase Assay]
[Cell Assay]
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.4±0.1 g/cm3
[ Molecular Formula ]:
C28H30ClN5O4S
[ Molecular Weight ]:
568.087
[ Exact Mass ]:
567.170715
[ PSA ]:
114.20000
[ LogP ]:
2.15
[ Index of Refraction ]:
1.664
[ Storage condition ]:
2-8°C
[ Water Solubility ]:
DMSO: 10 mg/mL at 60 °C
MSDS
Safety Information
[ Symbol ]:
GHS07
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H315-H319-H335
[ Precautionary Statements ]:
P261-P305 + P351 + P338
[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves
[ Hazard Codes ]:
Xi
[ Risk Phrases ]:
R36/37/38
[ Safety Phrases ]:
S26-S36
[ RIDADR ]:
NONH for all modes of transport
[ WGK Germany ]:
3
Articles
Cancer Biol. Ther. 16(1) , 170-5, (2015)
Vestibular schwannoma (VS), the fourth most common intracranial tumor, arises from the Schwann cells of the vestibular nerve. Although several pathways have been independently implicated in VS pathobi...
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.PLoS ONE 8(3) , e59708, (2013)
Epidermal growth factor receptor (EGFR) and c-MET receptors are expressed on many non-small cell lung cancer (NSCLC) cells. Current single agent therapeutic targeting of a mutant EGFR has a high effic...
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.Cancer Res. 65 , 1479-1488, (2005)
Non-small cell lung cancer (NSCLC) is a difficult disease to treat. The c-Met receptor is an attractive potential target for novel therapeutic inhibition in human cancers. We provide strong evidence t...